CLYM
Climb Bio IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$648.76M
P/E Ratio
—
EPS
$-0.77
Beta
0.03
52W High
$12.48
52W Low
$1.16
50-Day MA
$8.41
200-Day MA
$4.42
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Climb Bio Inc
Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. The company is headquartered in Wilmington, Delaware.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-67.79M |
| Operating Margin | 0.00% |
| Return on Equity | -32.20% |
| Return on Assets | -22.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $3.36 |
| Price-to-Book | 4.40 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | 0.58 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $57.26M |
| Float | $28.06M |
| % Insiders | 0.37% |
| % Institutions | 62.80% |
Historical Volatility
HV 10-Day
107.87%
HV 20-Day
83.47%
HV 30-Day
77.49%
HV 60-Day
75.46%
HV Rank
37.7%
Volatility is currently expanding
Analyst Ratings
Consensus ($19.58 target)
1
Strong Buy12
BuyMore HEALTHCARE Stocks
Data last updated: 5/16/2026